חוב לטווח קצר של החברה: Zentalis Pharmaceuticals (ZNTL)

The total short-term debt, which forms this chart via GURU.Markets data, demonstrates the current load, where the parameter value reaches 0.00. High costs for testing and FDA oversight create a defensive barrier for Zentalis Pharmaceuticals (ZNTL). However, the company is fighting a rigorous battle for patient survival, and the absence of commercial sales temporarily deprives it of the ability to exercise pricing power.

Liquidity is critical for the oncology biopharma Zentalis Pharmaceuticals (ZNTL), which depends on clinical trial outcomes and competition with big pharma. This short-term borrowing metric measures the volume of obligations maturing within one year, reflecting the burn rate of R&D capital. A downward trend in the curve indicates increasing financial stability, which minimizes bankruptcy risk in the event of delays in bringing drugs to market.